08:15 AM EDT, 09/11/2024 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) on Wednesday announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (EoE), an allergic condition that causes the esophagus to be inflamed and not contract properly.

The results from the fourth cohort of the RESOLVE trial involved patients that were administered 12 injections of 2.5 mg of EP-104GI. Patients reported less symptom severity, achieving levels comparable with currently approved therapies at 12 weeks post administration, Eupraxia said. The severity of EoE also showed the largest percentage reduction of any cohort to date, to levels comparable with currently approved therapies.

"The RESOLVE trial is progressing rapidly and we continue to observe positive data on efficacy and safe and we continue to observe positive data on efficacy and safety outcomes with EP-104GI, with the fifth cohort expected to read out in November 2024," said Eupraxia Chief Executive Dr. James Helliwell. "Overall, we are encouraged by the data that we have seen across a number of key metrics and remain optimistic that we'll see further improvements in patient response as the trial progresses towards an optimal dosing level."